

## Originalbeiträge in Fachzeitschriften (peer-reviewed)

Wild C, Sehic O, Schmidt L, & **Fabian, D.** (2024). Public Contributions to R&D of Medical Innovations: a Framework for Analysis. *Health policy*, 105235.  
<https://doi.org/https://doi.org/10.1016/j.healthpol.2024.105235>

**Fabian D** & Wild C (2024). Ownership changes in the pharmaceutical industry: Understanding the 2023 Pharma Mergers and Acquisitions Landscape of Europe. (submitted)

**Fabian D**, Sehic O & Wild C (2024). The Origins of Novo Nordisk and Novartis Products: Piloting a Framework to identify the public contributions. (submitted)

Schmidt L, Sehic O, Theuretzbacher U, **Fabian D** & Wild C (2024). Piloting a Framework for analysing the public contributions to R&D: new antibiotics in focus. (submitted)

Schmidt L., Sehic O, Theuretzbacher U, **Fabian D**, & Wild C (2025). 'Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus.' *Journal of Pharmaceutical Policy and Practice*, 18(1).  
<https://doi.org/10.1080/20523211.2024.2449045>

**Fabian D**, & Wild C (2024). Disaggregation Of The Costs Of Pharmaceutical Research And Development. *International Journal of Technology Assessment in Health Care*, 40(S1), S37–S37. <https://doi.org/10.1017/S0266462324001430>